A Power comparisons of iNOTE and iTEGS across additional simulation settings.
B Power simulations comparing variance-component-based total effect gene set testing procedures to existing methods under mixture disease-model settings
Power performance is shown in Figure B .1 for a gene set of size 3 with a 100% causal risk signal proportion of genes under the underlying disease risk model settings where all causal genes contribute to disease risk via a) an equal mixture of M and MG; b) an equal mixture of M and MGC; c) an equal mixture of MG and MGC.
In these additional mixture simulations, the power results for each method are similar to those presented in the main text. The iNOTE and iTEGS methods, including the poor-performing iTEGS-M for mixture-disease models, consistently outperform the Zhao and GSAA methods. Davies approximation p-values for for all significant gene sets after Bonferroni correction. N0: total no. of genes in the gene set; NT : total no. of genes with methylation and gene expression data available (i.e. tested); Q: the iTEGS Q-statistic test specifying M, G, MG, or MGC; Bonferroni adjusted p-value threshold was calculated as α/M = 5E − 04, where α = 0.05 and M is the total number of gene sets tested.
C Variance component-based total effect test p-values for gene
sets associated with lung cancer in TCGA subjects using the Davies approximation.
P-values calculated for the iTEGS tests using the Davies approximation are reported in Table C.1. As noted in the main text, the Davies approximations for iTEGS yield results that are similar to the empirical perturbation based iTEGS primarily when the gene set is small.
D Extensions to disease model selection panel in iTEGS and iN-OTE, with additional applications in KEGG and BIOCARTA pathways.
As gene-expression only models are also a commonly assumed disease-risk model in literature, and indeed may exhibit greater power when signal from DNAm sites is sparse, we extended the model search of both iNOTE algorithms, chi and uni, to also consider the gene-expression only model, denoted by Q G .
We used iTEGS, the extended disease-risk model panels for iNOTE, and GSAA to conduct ex- We conducted additional exploratory analyses in the MsigDB gene sets with known associations with lung cancer. In our additional analyses, we screened for gene sets associated with pathological stage of tumor at initial biopsy. Counts of total and overlapping gene sets identified by each method, iTEGS, iNOTE, and GSAA, are reported in Table E .1 and results for significant gene sets surviving Bonferroni correction in at least one iTEGS and at least one iNOTE test are reported in Table E .2. (2) 19 (0) 16 (2) 26 (2) 25 (2) Satterthwaite approximated p-values for all significant gene sets surviving Bonferroni correction in at least one iTEGS and one iNOTE approach. N0: total no. of genes in the gene set; NT : total no. of genes with methylation and gene expression data available (i.e. tested); Q: the iTEGS Q-statistic test specifying M, G, MG, or MGC; Bonferroni adjusted p-value threshold was calculated as α/M = 5E − 04, where α = 0.05 and M is the total number of gene sets tested. Model selection by the omnibus testing procedures include the Q G in consideration. (28) 33 (8) 58 (24) 63 (30) 61 (30) A total of 99 lung cancer associated gene sets were obtained and tested from MsigDB. Tests for iTEGS were calculated under disease-risk model specifications M: methylation effect only, G: mRNA expression effect only, MG: methyation and mRNA expression effects, and MGC: methylation effect, mRNA expression effect, and their interactions.The total and overlapping counts of significant gene sets identified by each method is reported here, with numbers in parentheses denoting the counts of gene sets that remain significant after Bonferroni correction. 
